<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Frequency Doubling Technology - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAUgfDwqCUnIlDdtIueAJgAAAAk","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Frequency_Doubling_Technology","wgTitle":"Frequency Doubling Technology","wgCurRevisionId":75955,"wgRevisionId":75955,"wgArticleId":4071,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Pages with reference errors","Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Frequency_Doubling_Technology","wgRelevantArticleId":4071,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],
"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},
"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Various testing modalities are currently available for detecting visual field loss. This page will focus specifically on the role of frequency doubling technology in assessing visual fields."/>
<meta name="date" content="2021-12-26"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Frequency Doubling Technology" href="/w/index.php?title=Special:ExportRDF/Frequency_Doubling_Technology&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Frequency_Doubling_Technology rootpage-Frequency_Doubling_Technology layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Frequency+Doubling+Technology" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Frequency+Doubling+Technology" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbprq0ync7"></button>
					<div class="collapse navbar-collapse hbprq0ync7" id="hbprq0ync7">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Frequency_Doubling_Technology" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Frequency_Doubling_Technology&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Frequency_Doubling_Technology&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Frequency_Doubling_Technology&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Frequency_Doubling_Technology&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Frequency_Doubling_Technology#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Frequency Doubling Technology</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Helen.Jiang" title="User:Helen.Jiang">Helen Jiang, MD</a>,&#8201;<a href="/User:Reena.Garg" title="User:Reena.Garg">Reena Garg, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:John.Davis.Akkara" title="User:John.Davis.Akkara">Dr John Davis Akkara (MBBS, MS, FAEH, FMRF)</a>,&#160;<a href="/User:Helen.Jiang" title="User:Helen.Jiang">Helen Jiang, MD</a>,&#160;<a href="/User:Qi.cui" title="User:Qi.cui">Qi N. Cui, MD PhD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Qi.cui" title="User:Qi.cui">Qi N. Cui, MD PhD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Update Pending</b>
</div>
</div>&#160;by <a href="/User:Qi.cui" title="User:Qi.cui">Qi N. Cui, MD PhD</a> on December 27, 2021.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Frequency_Doubling_Technology&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Frequency_Doubling_Technology&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table></div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Summary"><span class="tocnumber">1</span> <span class="toctext">Summary</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#The_field_of_vision_and_characteristics_of_visual_field_loss_in_glaucoma"><span class="tocnumber">2</span> <span class="toctext">The field of vision and characteristics of visual field loss in glaucoma</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Devices_and_Algorithm"><span class="tocnumber">3</span> <span class="toctext">Devices and Algorithm</span></a>
<ul>
<li class="toclevel-2 tocsection-4"><a href="#1st_generation_FDT_perimetry"><span class="tocnumber">3.1</span> <span class="toctext">1st generation FDT perimetry</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Second_generation_Humphrey_Matrix_FDT_perimetry"><span class="tocnumber">3.2</span> <span class="toctext">Second generation Humphrey Matrix FDT perimetry</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-6"><a href="#Testing_methods"><span class="tocnumber">4</span> <span class="toctext">Testing methods</span></a></li>
<li class="toclevel-1 tocsection-7"><a href="#Interpretation"><span class="tocnumber">5</span> <span class="toctext">Interpretation</span></a>
<ul>
<li class="toclevel-2 tocsection-8"><a href="#Reliability_indices"><span class="tocnumber">5.1</span> <span class="toctext">Reliability indices</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-9"><a href="#FDT_vs_SAP"><span class="tocnumber">6</span> <span class="toctext">FDT vs SAP</span></a></li>
<li class="toclevel-1 tocsection-10"><a href="#Uses_in_clinical_practice"><span class="tocnumber">7</span> <span class="toctext">Uses in clinical practice</span></a></li>
<li class="toclevel-1 tocsection-11"><a href="#References"><span class="tocnumber">8</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Summary">Summary</span></h1>
<p>Various testing modalities are currently available for detecting visual field loss. This page will focus specifically on the role of frequency doubling technology in assessing visual fields.
</p><p>Frequency doubling technology (FDT) perimetry is based on a flicker illusion created by counterphase flickering of a low spatial frequency sinusoidal grating at a high temporal frequency.<sup id="cite_ref-.E2.80.9DKelly1966_1-0" class="reference"><a href="#cite_note-.E2.80.9DKelly1966-1">&#91;1&#93;</a></sup> This phenomenon essentially creates an image that appears double its actual spatial frequency. 
</p><p>The frequency doubling illusion (see example <a rel="nofollow" class="external text" href="http://webeye.ophth.uiowa.edu/ips/perimetryhistory/FDP/">here</a>) has previously been attributed specifically to the nonlinear response of the My cells in the magnocellular layer.<sup id="cite_ref-.E2.80.9DMaddess1992_2-0" class="reference"><a href="#cite_note-.E2.80.9DMaddess1992-2">&#91;2&#93;</a></sup> This is significant because it suggests the ability of FDT to selectively detect loss of function in certain parts of the nerve fiber layer. However, several studies have questioned whether such a separate group of nonlinear ganglion cells truly exist, and it has instead been proposed that frequency doubling may be due to mechanisms elsewhere in the visual pathway (such as the cortex) rather than non-linear cells based in the retina.<sup id="cite_ref-.E2.80.9DZeppieri2008_3-0" class="reference"><a href="#cite_note-.E2.80.9DZeppieri2008-3">&#91;3&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DWhite2002_4-0" class="reference"><a href="#cite_note-.E2.80.9DWhite2002-4">&#91;4&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="The_field_of_vision_and_characteristics_of_visual_field_loss_in_glaucoma">The field of vision and characteristics of visual field loss in glaucoma</span></h1>
<p>The normal field of vision encompasses approximately 50 degrees nasal and superior, 70 degrees inferior, and 90 degrees temporal.<sup id="cite_ref-.E2.80.9DHeijl2002_5-0" class="reference"><a href="#cite_note-.E2.80.9DHeijl2002-5">&#91;5&#93;</a></sup> Sensitivity is greatest in the middle and declines toward the periphery, commonly referred to as the “hill of vision”. Visual field defects are considered to be any significant change in sensitivity from this normal hill of vision.
</p><p>Early glaucomatous nerve damage is thought to be due to loss of large-diameter retinal ganglion cells, namely the My cells of the magnocellular layer.<sup id="cite_ref-.E2.80.9DQuigley1988_6-0" class="reference"><a href="#cite_note-.E2.80.9DQuigley1988-6">&#91;6&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DJohnson1997_7-0" class="reference"><a href="#cite_note-.E2.80.9DJohnson1997-7">&#91;7&#93;</a></sup> These cells are responsible for a small proportion of the total retinal ganglion cells and have minimal functional redundancy, making them a good target for detecting early glaucoma damage.<sup id="cite_ref-.E2.80.9DJohnson1997_7-1" class="reference"><a href="#cite_note-.E2.80.9DJohnson1997-7">&#91;7&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DJohnson1994_8-0" class="reference"><a href="#cite_note-.E2.80.9DJohnson1994-8">&#91;8&#93;</a></sup>
</p><p>The earliest visual field defects in glaucoma have been described as the nasal step or paracentral scotoma, followed by extension of these defects centrally over time.<sup id="cite_ref-.E2.80.9DHart1982_9-0" class="reference"><a href="#cite_note-.E2.80.9DHart1982-9">&#91;9&#93;</a></sup> The inferior and superior nerve sectors have been reported to have the greatest amount of optic nerve damage in glaucoma. It has been postulated that the structure of the lamina cribrosa lends axons passing through these poles to be more susceptible to distortions caused by elevated IOP.<sup id="cite_ref-.E2.80.9DQuigley1982_10-0" class="reference"><a href="#cite_note-.E2.80.9DQuigley1982-10">&#91;10&#93;</a></sup> 
</p><p>Hart and Becker have described three phases of glaucomatous nerve damage.<sup id="cite_ref-.E2.80.9DHart1982_9-1" class="reference"><a href="#cite_note-.E2.80.9DHart1982-9">&#91;9&#93;</a></sup> Occult damage occurs in the first phase without detectable visual field loss. This may be due to the redundancy of the nerve fibers.<sup id="cite_ref-.E2.80.9DKerrigan-Baumrind2004_11-0" class="reference"><a href="#cite_note-.E2.80.9DKerrigan-Baumrind2004-11">&#91;11&#93;</a></sup> In the second phase, visual field loss is barely detectable, though it has been noted that deficits in color vision and decreased contrast sensitivity may be detected. In the third phase, visual field defects become manifest and extend to cover an entire Bjerrum, or arcuate region as they progress.<sup id="cite_ref-.E2.80.9DHart1982_9-2" class="reference"><a href="#cite_note-.E2.80.9DHart1982-9">&#91;9&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Devices_and_Algorithm">Devices and Algorithm</span></h1>
<p>The 2 commercial FDT perimeters available are the first generation Frequency Doubling Technology (Welch Allyn, Skaneateles, NY) and the second generation Humphrey Matrix (Carl Ziess Meditec, Inc., Dublin, CA). The machines are portable and can be set on a flat surface at sitting level for use. 
</p><p>More recently, iPad and smartphone based FDT testing are under development.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12">&#91;12&#93;</a></sup>,<sup id="cite_ref-13" class="reference"><a href="#cite_note-13">&#91;13&#93;</a></sup> If validated, such compact and portable FDT testing hold promise for improving accessibility and affordability in community-based glaucoma screening. 
</p>
<h2><span class="mw-headline" id="1st_generation_FDT_perimetry">1st generation FDT perimetry</span></h2>
<p><br />There are two different presentation patterns using the original FDT perimeter. The C-20 tests 17 different points within a central 20-degree radius (4 targets in each quadrant and one central target), while the N-30 incorporates two additional nasal targets above and below the horizontal meridian.<sup id="cite_ref-.E2.80.9DZeppieriWeb_14-0" class="reference"><a href="#cite_note-.E2.80.9DZeppieriWeb-14">&#91;14&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DJohnson2008_15-0" class="reference"><a href="#cite_note-.E2.80.9DJohnson2008-15">&#91;15&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DAnderson2003_16-0" class="reference"><a href="#cite_note-.E2.80.9DAnderson2003-16">&#91;16&#93;</a></sup> Both patterns can be used in screening or threshold testing. Good sensitivity and specificity for detecting glaucomatous change has been described using both screening and threshold testing.<sup id="cite_ref-.E2.80.9DCello2000_17-0" class="reference"><a href="#cite_note-.E2.80.9DCello2000-17">&#91;17&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DQuigley1998_18-0" class="reference"><a href="#cite_note-.E2.80.9DQuigley1998-18">&#91;18&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DBurnstein2000_19-0" class="reference"><a href="#cite_note-.E2.80.9DBurnstein2000-19">&#91;19&#93;</a></sup>
</p><p>In the first generation FDT perimeter, each target is displayed as a 10-degree-diameter square, with the exception of the central stimulus which is presented as a 5-degree-diameter circle. The 0.25 cycles/degree sinusoidal grating undergoes counterphase flicker at 25 Hz and lasts for 720msec. There is first a 160msec increase in contrast, then 400msec of steady presentation at the set contrast, followed by a 160msec decrease in contrast. Consecutive stimuli are separated by up to 500msec of variable pause in order to reduce the rhythmic responses. A button press by the patient between 100msec and one second after presentation is counted as stimuli detection, at which time the current stimulus will be discontinued to order to shorten testing time.<sup id="cite_ref-.E2.80.9DCello2000_17-1" class="reference"><a href="#cite_note-.E2.80.9DCello2000-17">&#91;17&#93;</a></sup>
</p><p>The original FDT perimeter threshold testing utilizes a four-reversal staircase procedure known as the modified binary search algorithm (MOBS).<sup id="cite_ref-.E2.80.9DZeppieriWeb_14-1" class="reference"><a href="#cite_note-.E2.80.9DZeppieriWeb-14">&#91;14&#93;</a></sup> In this way, contrast is decreased if the stimulus is detected at a higher level, or contrast is increased until a stimulus is detected.<sup id="cite_ref-.E2.80.9DCello2000_17-2" class="reference"><a href="#cite_note-.E2.80.9DCello2000-17">&#91;17&#93;</a></sup>
</p><p>Different types of screening protocols are available which vary by contrast level. 
</p><p>The N30-1 screening test presents stimuli that can be detected by 99% of the normal population adjusted for age.<sup id="cite_ref-.E2.80.9DAnderson2003_16-1" class="reference"><a href="#cite_note-.E2.80.9DAnderson2003-16">&#91;16&#93;</a></sup> If the initial target is not detected, the same stimulus is presented again. If the stimulus is again not detected, the target will be presented at a level detected by 99.5% of the normal population. If this target is not seen the stimulus is presented as maximum contrast. Sensitivity for the N30-1 test is been reported to be between 78-92% and specificity between 85-100%.<sup id="cite_ref-.E2.80.9DJohnson2008_15-1" class="reference"><a href="#cite_note-.E2.80.9DJohnson2008-15">&#91;15&#93;</a></sup> The high specificity associated with this test suggests it may be a useful option for large population screening.
</p><p>The N30-5 screening test presents stimuli that can be detected by 95% of the age-adjusted normal population.<sup id="cite_ref-.E2.80.9DAnderson2003_16-2" class="reference"><a href="#cite_note-.E2.80.9DAnderson2003-16">&#91;16&#93;</a></sup> If the initial target is not detected, the same stimulus is presented again. It the stimulus is again not detected, the target will be presented at a level detected by 98% of the normal population. If this target is not seen the stimulus is presented at the 99% detection level. The sensitivity for this test is reported to be 85-95% and the sensitivity between 80-90%.<sup id="cite_ref-.E2.80.9DJohnson2008_15-2" class="reference"><a href="#cite_note-.E2.80.9DJohnson2008-15">&#91;15&#93;</a></sup> The high sensitivity associated with this screening test suggests it to be better for detecting earlier visual field loss in glaucoma patients, rather than as a screening tool for the general population. 
</p><p>Both the N30-1 and N30-5 tests take about half a minute in each normal eye and up to 2 minutes for eyes with visual field defects.<sup id="cite_ref-.E2.80.9DJohnson2008_15-3" class="reference"><a href="#cite_note-.E2.80.9DJohnson2008-15">&#91;15&#93;</a></sup> Tests with targets at higher contrast levels are more specific for detecting patients with visual field defects while tests with lower contrast levels are more sensitive.
</p>
<h2><span class="mw-headline" id="Second_generation_Humphrey_Matrix_FDT_perimetry">Second generation Humphrey Matrix FDT perimetry</span></h2>
<p><br />The second generation Humphrey Matrix FDT Perimeter introduced several new features, including the ability to monitor eye fixation. Threshold testing on the Humphrey Matrix uses smaller targets that are presented along a grid. In addition, greater spatial resolution is available with 24-2, 30-2, 10-2, and macular threshold tests. The 24-2 and 30-2 threshold tests present 5 degree-diameter targets at a higher frequency 0.50 cycles/degree sinusoidal grating that undergoes counterphase flicker at 18Hz.<sup id="cite_ref-.E2.80.9DJohnson2008_15-4" class="reference"><a href="#cite_note-.E2.80.9DJohnson2008-15">&#91;15&#93;</a></sup> The 10-2 and macular tests present 2-degree-diameter targets at a counterphase frequency of 12Hz.<sup id="cite_ref-.E2.80.9DZeppieriWeb_14-2" class="reference"><a href="#cite_note-.E2.80.9DZeppieriWeb-14">&#91;14&#93;</a></sup> The N-30 threshold testing utilizes a two-reversal MOBS algorithm while the other threshold tests unique to the Humphrey Matrix utilize a Bayesian threshold estimation strategy (ZEST) similar to the Swedish Interactive Threshold Algorithm (SITA) used in the Humphrey Field Analyzer.<sup id="cite_ref-.E2.80.9DJohnson2008_15-5" class="reference"><a href="#cite_note-.E2.80.9DJohnson2008-15">&#91;15&#93;</a></sup> The 24-2 screening protocol, available on the Humphrey Matrix, utilizes the same principle as the N30 tests but presents 54 targets in a grid bracketing the vertical and horizontal meridians.<sup id="cite_ref-.E2.80.9DJohnson2008_15-6" class="reference"><a href="#cite_note-.E2.80.9DJohnson2008-15">&#91;15&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Testing_methods">Testing methods</span></h1>
<p>During FDT perimetry testing, the patient is presented different flicker targets and instructed to press the response button at the appearance of each stimulus. Due to the relatively large targets used in FDT perimetry, refractive errors up to 6 diopters are not considered to significantly influence test results.<sup id="cite_ref-.E2.80.9DAnderson2003_16-3" class="reference"><a href="#cite_note-.E2.80.9DAnderson2003-16">&#91;16&#93;</a></sup> Patients are able to wear their own corrective lenses while performing the test. 
</p><p>As described in the above section, the FDT perimeter can be used for screening or threshold testing. Screening protocols vary by contrast level. Tests with targets at higher contrast levels are more specific for detecting patients with visual field defects while tests with lower contrast levels are more sensitive. Both the N30-1 and N30-5 screening tests take about half a minute in each normal eye and up to 2 minutes for eyes with visual field defects.<sup id="cite_ref-.E2.80.9DJohnson2008_15-7" class="reference"><a href="#cite_note-.E2.80.9DJohnson2008-15">&#91;15&#93;</a></sup> Threshold testing gives the lowest contrast sensitivity required to detect the FDT stimulus at each point. Threshold testing takes approximately 5 minutes per eye using the Humphrey Matrix 24-2 protocol.<sup id="cite_ref-.E2.80.9DJohnson2008_15-8" class="reference"><a href="#cite_note-.E2.80.9DJohnson2008-15">&#91;15&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Interpretation">Interpretation</span></h1>
<p>Results from FDT perimetry are reported using decibels of sensitivity. FDT perimetry has a manufacturer-provided internal normative database. The global indices that are reported are the mean deviation (MD) and pattern standard deviation (PSD). Mean deviation (MD) reports the amount the entire field deviates from normal, and pattern standard deviation (PSD) demonstrates irregularities within the field such as a localized defect.<sup id="cite_ref-.E2.80.9DHeijl2002_5-1" class="reference"><a href="#cite_note-.E2.80.9DHeijl2002-5">&#91;5&#93;</a></sup>
</p><p>Quigley noted that the presence of two or more defective locations on FDT screening testing gave the best performance criterion with sensitivity of 91% and specificity of 94% for detecting patients with glaucomatous field loss.<sup id="cite_ref-.E2.80.9DQuigley1998_18-1" class="reference"><a href="#cite_note-.E2.80.9DQuigley1998-18">&#91;18&#93;</a></sup> Patel et al. created an algorithm that gave more weight to locations near the center as well as denser field defects and reported sensitivity of 80.5% and specificity 95% for detecting glaucomatous changes using this formula.<sup id="cite_ref-.E2.80.9DPatel2000_20-0" class="reference"><a href="#cite_note-.E2.80.9DPatel2000-20">&#91;20&#93;</a></sup> Another study looked at previously suggested algorithms for FDT interpretation in the literature and found no significant difference in diagnostic performance.<sup id="cite_ref-.E2.80.9DMuskens2004_21-0" class="reference"><a href="#cite_note-.E2.80.9DMuskens2004-21">&#91;21&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Reliability_indices">Reliability indices</span></h2>
<p><br />False-positives are detected when a patient responds to a stimulus of zero contrast. False-negatives are recorded when a patient does not respond to a stimulus of maximum contrast, though such a result may be recorded in patients with significant vision loss who are responding reliably.<sup id="cite_ref-.E2.80.9DAnderson2003_16-4" class="reference"><a href="#cite_note-.E2.80.9DAnderson2003-16">&#91;16&#93;</a></sup>
</p><p>Fixation losses are noted when a patient detects a 1 degree target at 50% contrast in the area of the physiological blind spot. As the first generation FDT perimeter does not have the ability to monitor fixation, it is possible that patients with stable fixation outside the expected position range will be recorded as having fixation loss.<sup id="cite_ref-.E2.80.9DAnderson2003_16-5" class="reference"><a href="#cite_note-.E2.80.9DAnderson2003-16">&#91;16&#93;</a></sup> Due to the fact that only three trials are used to calculate each reliability index, it has been recommended that tests with even one false-positive be repeated to ensure more accurate results.<sup id="cite_ref-.E2.80.9DAnderson2003_16-6" class="reference"><a href="#cite_note-.E2.80.9DAnderson2003-16">&#91;16&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="FDT_vs_SAP">FDT vs SAP</span></h1>
<p>Many studies evaluating FDT use in glaucoma have used standard automated perimetry (SAP) as the gold standard to compare visual field loss detection. FDT results have been reported to correlate strongly with defects detected using SAP.<sup id="cite_ref-.E2.80.9DCasson2001_22-0" class="reference"><a href="#cite_note-.E2.80.9DCasson2001-22">&#91;22&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DArtes2005_23-0" class="reference"><a href="#cite_note-.E2.80.9DArtes2005-23">&#91;23&#93;</a></sup> A study comparing second generation FDT 24-2 testing with SAP 24-2 testing demonstrated strong correlation in patients with early to moderate glaucomatous field loss.<sup id="cite_ref-.E2.80.9DLeeprechanon2007_24-0" class="reference"><a href="#cite_note-.E2.80.9DLeeprechanon2007-24">&#91;24&#93;</a></sup>
</p><p>Beyond simple correlation with SAP, several studies have shown FDT to be more sensitive for detecting early visual field loss compared to SAP when structural optic disc abnormality or RNFL appearance are used to define glaucomatous neuropathy.<sup id="cite_ref-.E2.80.9DSample2000_25-0" class="reference"><a href="#cite_note-.E2.80.9DSample2000-25">&#91;25&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DBrusini2006_26-0" class="reference"><a href="#cite_note-.E2.80.9DBrusini2006-26">&#91;26&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DRacette2008_27-0" class="reference"><a href="#cite_note-.E2.80.9DRacette2008-27">&#91;27&#93;</a></sup>
</p><p>A longitudinal study by Medeiros et al. followed a group of glaucoma suspects with baseline normal visual fields using SAP testing.<sup id="cite_ref-.E2.80.9DMedeiros2004_28-0" class="reference"><a href="#cite_note-.E2.80.9DMedeiros2004-28">&#91;28&#93;</a></sup> The authors found that 59% of the patients who subsequently developed defects on SAP had FDT abnormalities that preceded the SAP visual field losses by up to 4 years. However, the study also reported that 18% of SAP converters were not found to have repeatable abnormalities on FDT.<sup id="cite_ref-.E2.80.9DMedeiros2004_28-1" class="reference"><a href="#cite_note-.E2.80.9DMedeiros2004-28">&#91;28&#93;</a></sup>
</p><p>One advantage of FDT perimetry is that it can be completed faster than using the SAP SITA-FAST strategy.<sup id="cite_ref-.E2.80.9DWadood2002_29-0" class="reference"><a href="#cite_note-.E2.80.9DWadood2002-29">&#91;29&#93;</a></sup> The FDT machine is also more portable compared to the Humphrey Field Analyzer. FDT has been reported to have both lower intra- and inter-test variability compared to SAP, which suggests it may be a useful test to monitor long-term progression of visual field loss.<sup id="cite_ref-.E2.80.9DSpry2001_30-0" class="reference"><a href="#cite_note-.E2.80.9DSpry2001-30">&#91;30&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Uses_in_clinical_practice">Uses in clinical practice</span></h1>
<p>Frequency doubling technology has been presented by many as an effective method for detecting glaucomatous changes given the relatively inexpensive, efficient, and non-operator dependent nature of the test. FDT also allows subjects to wear their own spectacle correction and is also unaffected by blur up to 6 or 7 diopters. The FDT machines are relatively portable (Humphrey FDT weight 19 pounds and Humphrey Matrix 30 pounds),<sup id="cite_ref-.E2.80.9DZeiss2015_31-0" class="reference"><a href="#cite_note-.E2.80.9DZeiss2015-31">&#91;31&#93;</a></sup> a benefit further enhanced by newer smartphone and iPad-based algorithms, and thus may lend itself to use in community screenings for glaucoma.
</p><p>Several studies in the literature have demonstrated the FDT perimeter to be a reliable and efficient way to screen for glaucomatous changes.<sup id="cite_ref-.E2.80.9DJohnson1997_7-2" class="reference"><a href="#cite_note-.E2.80.9DJohnson1997-7">&#91;7&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DTrible2000_32-0" class="reference"><a href="#cite_note-.E2.80.9DTrible2000-32">&#91;32&#93;</a></sup> Quigley reported the average testing time for one eye using FDT perimetry to be 1.8 +/- 0.7 minutes, supporting the efficiency of this test.<sup id="cite_ref-.E2.80.9DQuigley1998_18-2" class="reference"><a href="#cite_note-.E2.80.9DQuigley1998-18">&#91;18&#93;</a></sup> The same author also noted that the presence of two or more defective locations on FDT testing gave the best performance criterion with sensitivity of 91% and specificity of 94% for detecting patients with glaucomatous field loss.<sup id="cite_ref-.E2.80.9DQuigley1998_18-3" class="reference"><a href="#cite_note-.E2.80.9DQuigley1998-18">&#91;18&#93;</a></sup> A prospective trial performed by Cello et al. compared FDT perimetry results from 254 normal eyes with 230 eyes with early, moderate, or advanced glaucoma.<sup id="cite_ref-.E2.80.9DCello2000_17-3" class="reference"><a href="#cite_note-.E2.80.9DCello2000-17">&#91;17&#93;</a></sup> The authors demonstrated sensitivity and specificity levels of over 97% when using FDT perimetry to detect moderate to advanced glaucoma damage. Sensitivity and specificity for detecting early glaucomatous changes were reported to be 85% and 90%, respectively.<sup id="cite_ref-.E2.80.9DCello2000_17-4" class="reference"><a href="#cite_note-.E2.80.9DCello2000-17">&#91;17&#93;</a></sup> 
</p><p>Several studies have reported that FDT use for glaucoma mass screening demonstrates reasonable performance given the resulting positive predictive value.<sup id="cite_ref-.E2.80.9DIawsaki2002_33-0" class="reference"><a href="#cite_note-.E2.80.9DIawsaki2002-33">&#91;33&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DAllen2002_34-0" class="reference"><a href="#cite_note-.E2.80.9DAllen2002-34">&#91;34&#93;</a></sup> In contrast, Boland et al., in an reanalysis of the data from the 6797 participants in the 2005-2008 cycles of the National Health and Nutrition Examination Survey (NHANES), concluded that FDT perimetry lacks both sensitivity and specificity for glaucoma screening in a population-based setting. In this study, 25% of NHANES participants were unable to complete FDT testing.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35">&#91;35&#93;</a></sup>
</p><p>Beyond screening for and monitoring the progression of glaucoma, FDT perimetry may also be applied for use in other ophthalmic pathologies. FDT has also been shown to correlate with SAP in detecting visual field defects secondary to neuro-ophthalmologic disorders.<sup id="cite_ref-.E2.80.9DWall2002_36-0" class="reference"><a href="#cite_note-.E2.80.9DWall2002-36">&#91;36&#93;</a></sup>
Reduced sensitivity on FDT perimetry has been reported in patients with diabetes compared to age matched controls,<sup id="cite_ref-.E2.80.9DJackson2012_37-0" class="reference"><a href="#cite_note-.E2.80.9DJackson2012-37">&#91;37&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DParikh2006_38-0" class="reference"><a href="#cite_note-.E2.80.9DParikh2006-38">&#91;38&#93;</a></sup>,<sup id="cite_ref-.E2.80.9DParravano2008_39-0" class="reference"><a href="#cite_note-.E2.80.9DParravano2008-39">&#91;39&#93;</a></sup> suggesting a role for FDT perimetry in screening for diabetic retinopathy. 
</p>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-.E2.80.9DKelly1966-1"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DKelly1966_1-0">↑</a></span> <span class="reference-text"> Kelly DH. Frequency doubling in visual responses. J Opt Soc Am. 1966;56:1628–1633.</span>
</li>
<li id="cite_note-.E2.80.9DMaddess1992-2"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DMaddess1992_2-0">↑</a></span> <span class="reference-text"> Maddess T, Henry GH. Performance of nonlinear visual units in ocular hypertension and glaucoma. Clinical Vision Science. 1992;7:371-383. </span>
</li>
<li id="cite_note-.E2.80.9DZeppieri2008-3"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DZeppieri2008_3-0">↑</a></span> <span class="reference-text"> Zeppieri M, Demirel S, Kent K, Johnson CA. Perceived spatial frequency of sinusoidal gratings. Optometry and Vision Science. 2008;85:318-329. </span>
</li>
<li id="cite_note-.E2.80.9DWhite2002-4"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DWhite2002_4-0">↑</a></span> <span class="reference-text"> White AJR, Sun H, Swanson WH, Lee BB. An examination of physiological mechanisms underlying the frequency-doubling illusion. Invest Ophthalmol Vis Sci. 2002;43:3590-3599. </span>
</li>
<li id="cite_note-.E2.80.9DHeijl2002-5"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-.E2.80.9DHeijl2002_5-0">5.0</a></sup> <sup><a href="#cite_ref-.E2.80.9DHeijl2002_5-1">5.1</a></sup></span> <span class="reference-text"> Heijl A, Patella VM. Essential Perimetry: The Field Analyzer Primer. 3rd ed. Dublin, CA: Carl Zeiss Meditec;2002.</span>
</li>
<li id="cite_note-.E2.80.9DQuigley1988-6"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DQuigley1988_6-0">↑</a></span> <span class="reference-text"> Quigley HA, Dunkelberger GR, Green WR. Chronic human glaucoma causing selectively greater loss of large optic nerve fibers. Ophthalmology. 1988;95:357-363. </span>
</li>
<li id="cite_note-.E2.80.9DJohnson1997-7"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-.E2.80.9DJohnson1997_7-0">7.0</a></sup> <sup><a href="#cite_ref-.E2.80.9DJohnson1997_7-1">7.1</a></sup> <sup><a href="#cite_ref-.E2.80.9DJohnson1997_7-2">7.2</a></sup></span> <span class="reference-text"> Johnson CA, Samules SJ. Screening for glaucomatous visual field loss with frequency-doubling perimetry. Investigative Ophthalmology &amp; Visual Science. 1997;38:413-425. </span>
</li>
<li id="cite_note-.E2.80.9DJohnson1994-8"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DJohnson1994_8-0">↑</a></span> <span class="reference-text"> Johnson CA. Selective versus nonselective losses in glaucoma. J Glaucoma (Suppl).1994;3:S32-S44. </span>
</li>
<li id="cite_note-.E2.80.9DHart1982-9"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-.E2.80.9DHart1982_9-0">9.0</a></sup> <sup><a href="#cite_ref-.E2.80.9DHart1982_9-1">9.1</a></sup> <sup><a href="#cite_ref-.E2.80.9DHart1982_9-2">9.2</a></sup></span> <span class="reference-text"> Hart WM, Becker B. The onset and evolution of glaucomatous visual field defects. Ophthalmology. 1982;89:268-279. </span>
</li>
<li id="cite_note-.E2.80.9DQuigley1982-10"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DQuigley1982_10-0">↑</a></span> <span class="reference-text"> Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol. 1982;100:135-146. </span>
</li>
<li id="cite_note-.E2.80.9DKerrigan-Baumrind2004-11"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DKerrigan-Baumrind2004_11-0">↑</a></span> <span class="reference-text"> Kerrigan-Baumrind LA, Quigley HA, Pease ME, Kerrigan DF, Mitchell RS. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest Ophthalmol Vis Sci. 2004;41:741-748. </span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><a href="#cite_ref-12">↑</a></span> <span class="reference-text">Alawa KA, Nolan RP, Han E, Arboleda A, Durkee H, Sayed MS, Aguilar MC, Lee RK. Low-cost, smartphone-based frequency doubling technology visual field testing using a head-mounted display. Br J Ophthalmol. 2021 Mar;105(3):440-444. doi: 10.1136/bjophthalmol-2019-314031. Epub 2019 Sep 17. PMID: 31530566.</span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><a href="#cite_ref-13">↑</a></span> <span class="reference-text">Kitayama K, Young AG, Ochoa A 3rd, Yu F, Wong KY, Coleman AL. The Agreement Between an iPad Visual Field App and Humphrey Frequency Doubling Technology in Visual Field Screening at Health Fairs. J Glaucoma. 2021 Sep 1;30(9):846-850. doi: 10.1097/IJG.0000000000001902. PMID: 34172631.</span>
</li>
<li id="cite_note-.E2.80.9DZeppieriWeb-14"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-.E2.80.9DZeppieriWeb_14-0">14.0</a></sup> <sup><a href="#cite_ref-.E2.80.9DZeppieriWeb_14-1">14.1</a></sup> <sup><a href="#cite_ref-.E2.80.9DZeppieriWeb_14-2">14.2</a></sup></span> <span class="reference-text"> Zeppieri M, Johnson CA. Frequency doubling technology (FDT) perimetry. <a rel="nofollow" class="external free" href="http://webeye.ophth.uiowa.edu/IPS/PerimetryHistory/FDP/index.htm">http://webeye.ophth.uiowa.edu/IPS/PerimetryHistory/FDP/index.htm</a>. Published 2008. Accessed December 27, 2021.  <span class="error mw-ext-cite-error" lang="en" dir="ltr">Cite error: Invalid <code>&lt;ref&gt;</code> tag; name "”ZeppieriWeb" defined multiple times with different content</span> <span class="error mw-ext-cite-error" lang="en" dir="ltr">Cite error: Invalid <code>&lt;ref&gt;</code> tag; name "”ZeppieriWeb" defined multiple times with different content</span></span>
</li>
<li id="cite_note-.E2.80.9DJohnson2008-15"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-.E2.80.9DJohnson2008_15-0">15.0</a></sup> <sup><a href="#cite_ref-.E2.80.9DJohnson2008_15-1">15.1</a></sup> <sup><a href="#cite_ref-.E2.80.9DJohnson2008_15-2">15.2</a></sup> <sup><a href="#cite_ref-.E2.80.9DJohnson2008_15-3">15.3</a></sup> <sup><a href="#cite_ref-.E2.80.9DJohnson2008_15-4">15.4</a></sup> <sup><a href="#cite_ref-.E2.80.9DJohnson2008_15-5">15.5</a></sup> <sup><a href="#cite_ref-.E2.80.9DJohnson2008_15-6">15.6</a></sup> <sup><a href="#cite_ref-.E2.80.9DJohnson2008_15-7">15.7</a></sup> <sup><a href="#cite_ref-.E2.80.9DJohnson2008_15-8">15.8</a></sup></span> <span class="reference-text"> Johnson CA. FDT perimetry for the detection of glaucomatous visual field loss. Glaucoma Today. 2008:26-28 </span>
</li>
<li id="cite_note-.E2.80.9DAnderson2003-16"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-.E2.80.9DAnderson2003_16-0">16.0</a></sup> <sup><a href="#cite_ref-.E2.80.9DAnderson2003_16-1">16.1</a></sup> <sup><a href="#cite_ref-.E2.80.9DAnderson2003_16-2">16.2</a></sup> <sup><a href="#cite_ref-.E2.80.9DAnderson2003_16-3">16.3</a></sup> <sup><a href="#cite_ref-.E2.80.9DAnderson2003_16-4">16.4</a></sup> <sup><a href="#cite_ref-.E2.80.9DAnderson2003_16-5">16.5</a></sup> <sup><a href="#cite_ref-.E2.80.9DAnderson2003_16-6">16.6</a></sup></span> <span class="reference-text"> Anderson AJ, Johnson CA. Frequency-doubling technology perimetry. Ophthalmol Clin N Am. 2003;16:213-225. </span>
</li>
<li id="cite_note-.E2.80.9DCello2000-17"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-.E2.80.9DCello2000_17-0">17.0</a></sup> <sup><a href="#cite_ref-.E2.80.9DCello2000_17-1">17.1</a></sup> <sup><a href="#cite_ref-.E2.80.9DCello2000_17-2">17.2</a></sup> <sup><a href="#cite_ref-.E2.80.9DCello2000_17-3">17.3</a></sup> <sup><a href="#cite_ref-.E2.80.9DCello2000_17-4">17.4</a></sup></span> <span class="reference-text"> Cello KE, Nelson-Quigg JM, Johnson CA. Frequency doubling technology perimetry for detection of glaucomatous field loss. American Journal of Ophthalmology 2000;129:314-322. </span>
</li>
<li id="cite_note-.E2.80.9DQuigley1998-18"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-.E2.80.9DQuigley1998_18-0">18.0</a></sup> <sup><a href="#cite_ref-.E2.80.9DQuigley1998_18-1">18.1</a></sup> <sup><a href="#cite_ref-.E2.80.9DQuigley1998_18-2">18.2</a></sup> <sup><a href="#cite_ref-.E2.80.9DQuigley1998_18-3">18.3</a></sup></span> <span class="reference-text"> Quigley HA. Identification of glaucoma-related visual field abnormality with the screening protocol of frequency doubling technology. American Journal of Ophthalmology. 1998;125:819-829. </span>
</li>
<li id="cite_note-.E2.80.9DBurnstein2000-19"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DBurnstein2000_19-0">↑</a></span> <span class="reference-text"> Burnstein Y, Ellish NJ, Magbalon M, Higginbotham EJ. Comparison of frequency doubling perimetry with humphrey visual field analysis in a glaucoma practice. American Journal of Ophthalmology.2000;129:328-333. </span>
</li>
<li id="cite_note-.E2.80.9DPatel2000-20"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DPatel2000_20-0">↑</a></span> <span class="reference-text"> Patel SC, Friedman DS, Varadkar P, Robin AL. Algorithm for interpreting the results of frequency doubling perimetry. American Journal of Ophthalmology.2000;129:323-327. </span>
</li>
<li id="cite_note-.E2.80.9DMuskens2004-21"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DMuskens2004_21-0">↑</a></span> <span class="reference-text"> Muskens RPHM, Heeg GP, Jansonius NM. An evaluation of algorithms designed to classify the results from frequency doubling perimetry. Ophthal Physiol Opt. 2004;24:498-503. </span>
</li>
<li id="cite_note-.E2.80.9DCasson2001-22"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DCasson2001_22-0">↑</a></span> <span class="reference-text"> Casson R, James B, Rubinstein A, Ali H. Clinical comparison of frequency doubling technology perimetry and Humphrey perimetry. Br J Ophthalmol..2001;85:360-362. </span>
</li>
<li id="cite_note-.E2.80.9DArtes2005-23"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DArtes2005_23-0">↑</a></span> <span class="reference-text"> Artes PH, Hutchison DM, Nicolela MT, et al. Threshold and variability properties of matrix frequency-doubling technology and standard automated perimetry  in glaucoma. Invest Ophthalmol Vis Sci. 2005;46:2451–2457. </span>
</li>
<li id="cite_note-.E2.80.9DLeeprechanon2007-24"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DLeeprechanon2007_24-0">↑</a></span> <span class="reference-text"> Leeprechanon N, Giangiacomo A, Fontana H, Hoffman D, Caprioli J. Frequency-doubling perimetry: comparison with standard automated perimetry to detect glaucoma. Am J Ophthalmol. 2007;143:263-271. </span>
</li>
<li id="cite_note-.E2.80.9DSample2000-25"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DSample2000_25-0">↑</a></span> <span class="reference-text"> Sample PA, Bosworth CF, Blumenthal EZ, Girkin C, Weinreb RN. Visual function-specific  perimetry for indirect comparison of different ganglion cell populations in glaucoma. Invest Ophthalmol Vis Sci.2000;41:1783-1790. </span>
</li>
<li id="cite_note-.E2.80.9DBrusini2006-26"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DBrusini2006_26-0">↑</a></span> <span class="reference-text"> Brusini P, Salvetat ML, Zeppieri M, Parisi L. Frequency doubling technology perimetry with the humphrey matrix 30-2 test. J Glaucoma. 2006;15:77-83. </span>
</li>
<li id="cite_note-.E2.80.9DRacette2008-27"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DRacette2008_27-0">↑</a></span> <span class="reference-text"> Racette L, Medeiros, FA, Zangwill LM, Ng D, Weinreb RN, Sample PA. Diagnostic accuracy of the matrix 24-2 and original N-30 frequency-doubling technology tests compared with standard automated perimetry. Invest Ophthalmol Vis Sci. 2008;49:954-960. </span>
</li>
<li id="cite_note-.E2.80.9DMedeiros2004-28"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-.E2.80.9DMedeiros2004_28-0">28.0</a></sup> <sup><a href="#cite_ref-.E2.80.9DMedeiros2004_28-1">28.1</a></sup></span> <span class="reference-text"> Medeiros, FA, Sample PA, Weinreb RN. Frequency doubling technology perimetry abnormalities as predictors of glaucomatous visual field loss. American Journal of Ophthalmology. 2004;137:863-871. </span>
</li>
<li id="cite_note-.E2.80.9DWadood2002-29"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DWadood2002_29-0">↑</a></span> <span class="reference-text"> Wadood AC, Azuara-Blanco A, Aspinall P, Taguri A, King AJW. Sensitivity and specificity of frequency-doubling technology, tendency-oriented perimetry, and humphrey swedish interactive threshold algorithm-fast perimetry in a glaucoma practice. American Journal of Ophthalmology.2002;133:327-332. </span>
</li>
<li id="cite_note-.E2.80.9DSpry2001-30"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DSpry2001_30-0">↑</a></span> <span class="reference-text"> Spry PGD, Johnson CA, McKendrick AM, Turpin A. Variability components of standard automated perimetry and frequency-doubling technology perimetry. Invest Ophthalmol Vis Sci.2001;42:1404-1410. </span>
</li>
<li id="cite_note-.E2.80.9DZeiss2015-31"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DZeiss2015_31-0">↑</a></span> <span class="reference-text"> <a rel="nofollow" class="external free" href="http://www.zeiss.com/meditec/en_us/products---solutions/ophthalmology-optometry/glaucoma/diagnostics/perimetry/humphrey-fdt.html">http://www.zeiss.com/meditec/en_us/products---solutions/ophthalmology-optometry/glaucoma/diagnostics/perimetry/humphrey-fdt.html</a> </span>
</li>
<li id="cite_note-.E2.80.9DTrible2000-32"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DTrible2000_32-0">↑</a></span> <span class="reference-text"> Trible JR, Schultz RO, Robinson JC, Rothe TL. Accuracy of glaucoma detection with frequency-doubling perimetry. Am J Ophthalmol 2000;129:740-745. </span>
</li>
<li id="cite_note-.E2.80.9DIawsaki2002-33"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DIawsaki2002_33-0">↑</a></span> <span class="reference-text"> Iawsaki A, Sugita M. Performance of glaucoma mass screening with only a visual field test using frequency-doubling technology perimetry. American Journal of Ophthalmology.2002;134:529-537. </span>
</li>
<li id="cite_note-.E2.80.9DAllen2002-34"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DAllen2002_34-0">↑</a></span> <span class="reference-text"> Allen, CS, Sponsel WE, Trigo Y, Dirks MS, Flynn WJ. Comparison of the frequency doubling technology screening algorithm and the humphrey 24-2 SITA-FAST in a large eye screening. Clinical and Experimental Ophthalmology 2002;30:8-14. </span>
</li>
<li id="cite_note-35"><span class="mw-cite-backlink"><a href="#cite_ref-35">↑</a></span> <span class="reference-text">Boland MV, Gupta P, Ko F, Zhao D, Guallar E, Friedman DS. Evaluation of Frequency-Doubling Technology Perimetry as a Means of Screening for Glaucoma and Other Eye Diseases Using the National Health and Nutrition Examination Survey. JAMA Ophthalmol. 2016 Jan;134(1):57-62. doi: 10.1001/jamaophthalmol.2015.4459. PMID: 26562502.</span>
</li>
<li id="cite_note-.E2.80.9DWall2002-36"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DWall2002_36-0">↑</a></span> <span class="reference-text"> Wall M, Neahring RK, Woodward KR. Sensitivity and specificity of frequency doubling perimetry  in neuro-ophthalmic disorders: a comparison with conventional automated perimetry. Invest Ophthalmol Vis Sci 2002;43:1277-1283. </span>
</li>
<li id="cite_note-.E2.80.9DJackson2012-37"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DJackson2012_37-0">↑</a></span> <span class="reference-text"> Jackson GR, Scott IU, Quillen DA et al. Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy. Br J Ophthalmol 2012;96:699-703. </span>
</li>
<li id="cite_note-.E2.80.9DParikh2006-38"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DParikh2006_38-0">↑</a></span> <span class="reference-text"> Parikh R, Naik M, Mathai A et al. Fole of frequency doubling technology perimetry in screening of diabetic retinopathy. Indian J Ophthal 2006;54:17-22. </span>
</li>
<li id="cite_note-.E2.80.9DParravano2008-39"><span class="mw-cite-backlink"><a href="#cite_ref-.E2.80.9DParravano2008_39-0">↑</a></span> <span class="reference-text"> Parravano M, Oddone F, Mineo D et al. The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes. Br J Ophthalmol 2008;92:1656-1660. </span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230305230637
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.001 seconds
CPU time usage: 0.203 seconds
Real time usage: 0.220 seconds
Preprocessor visited node count: 1022/1000000
Post‐expand include size: 5787/2097152 bytes
Template argument size: 1096/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 25366/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%   88.807      1 Template:Article
100.00%   88.807      1 -total
 85.72%   76.125      4 Template:Infobox_section
 26.24%   23.300      7 Template:UserLookup
  4.62%    4.102      1 Template:Review_expired
  1.53%    1.361      1 Template:Get_active_contest
  1.00%    0.892      1 Template:Infobox_begin
  0.87%    0.777      1 Template:Infobox_end
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Frequency_Doubling_Technology&amp;oldid=75955">https://eyewiki.org/w/index.php?title=Frequency_Doubling_Technology&amp;oldid=75955</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/w/index.php?title=Category:Pages_with_reference_errors&amp;action=edit&amp;redlink=1" class="new" title="Category:Pages with reference errors (page does not exist)">Pages with reference errors</a></li><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbprq0yosu">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Frequency_Doubling_Technology" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Frequency_Doubling_Technology" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Frequency_Doubling_Technology&amp;oldid=75955" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Frequency_Doubling_Technology&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on December 27, 2021, at 09:55.</div>
					<div>This page has been accessed 82,068 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.001},"limitreport":{"cputime":"0.203","walltime":"0.220","ppvisitednodes":{"value":1022,"limit":1000000},"postexpandincludesize":{"value":5787,"limit":2097152},"templateargumentsize":{"value":1096,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":25366,"limit":5000000},"timingprofile":["100.00%   88.807      1 Template:Article","100.00%   88.807      1 -total"," 85.72%   76.125      4 Template:Infobox_section"," 26.24%   23.300      7 Template:UserLookup","  4.62%    4.102      1 Template:Review_expired","  1.53%    1.361      1 Template:Get_active_contest","  1.00%    0.892      1 Template:Infobox_begin","  0.87%    0.777      1 Template:Infobox_end"]},"cachereport":{"timestamp":"20230305230637","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":541});});</script></body>
</html>